HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life

Mucosal Immunology

Volumn 6, Issue 4, 2013, Pages 692-703

  Yates, N L ^a   Stacey, A R ^b   Nolen, T L ^c   Vandergrift, N A ^a   Moody, M A ^a   Montefiori, D C ^a   Weinhold, K J ^a   Blattner, W A ^d   Borrow, P ^b   Shattock, R ^e   Cohen, M S ^f   Haynes, B F ^a   Tomaras, G D ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c RTI INTERNATIONAL   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; GLYCOPROTEIN GP 41; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY;

ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; NONHUMAN; PRIORITY JOURNAL; SEMINAL PLASMA; VAGINAL LAVAGE; VIRUS TRANSMISSION;

EID: 84878440866     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2012.107     Document Type: Article

References (69)

1. Cerutti, A. The regulation of IgA class switching. Nat Rev Immunol 8, 421-434 (2008).
2. Haase, A. Protection from HIV: Targeted Intervention Strategies. Whistler Conference Centre, British Columbia (2011).
3. Bomsel, M.etal. Immunization with HIV-1 gp41 subunitvirosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 34, 269-280 (2011).
4. Tomaras, G.D. et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 82, 12449-12463 (2008).
5. Moir, S. & Fauci, A.S. B cells inHIV infection and disease. Nat Rev Immunol 9, 235-245 (2009).
6. McMichael, A.J., Borrow, P., Tomaras, G.D., Goonetilleke, N. & Haynes, B.F The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 10, 11-23 (2010).
7. Fauci, A.S. Immunopathogenesis of HIV infection. J Acquir Immune Defic Syndr 6, 655-662 (1993).
8. Lim, S.G. et al. Loss of mucosal CD4 lymphocytes is an early feature of HIV infection. Clinical and Exp Immunol 92, 448-454 (1993).
9. Guadalupe, M. et al. Severe CD4 + T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 77, 11708-11717 (2003).
10. Brenchley, J.M. etal.CD4 + Tcell depletion duringall stagesofHIV disease occurs predominantlyinthegastrointestinal tract.J Exp Med 200, 749-759 (2004).
11. Brenchley, J.M. et al. Preferential infection shortens the life span of human immunodeficiency virus-specific CD4+ T cells in vivo. J Virol 80, 6801-6809 (2006).
12. Lore, K., Smed-Sorensen, A., Vasudevan, J., Mascola, J.R. & Koup, R.A. Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ T cells. J Exp Med 201, 2023-2033 (2005).
13. Lane, H.C.et al. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome.N Eng J Med 309, 453-458 (1983).
14. Moir, S. et al. HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci USA 98, 10362-10367 (2001).
15. Levesque, M.C. et al. Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med 6, e1000107 (2009).
16. Pahwa, S., Pahwa, R., Good, R.A., Gallo, R.C. & Saxinger, C. Stimulatory and inhibitory influences of human immunodeficiency virus on normal B lymphocytes. Proc Natl Acad Sci USA 83, 9124-9128 (1986).
17. Patke, C.L. & Shearer, W.T. gp120-and TNF-alpha-induced modulation of human B cell function: proliferation, cyclic AMP generation, Ig production, and B-cell receptor expression. J Allergy Clin Immunol 105, 975-982 (2000).
18. He, B. et al. HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J Immunol 176, 3931-3941 (2006).
19. Swingler, S. et al. Evidence for a pathogenic determinant in HIV-1 Nef involved in B cell dysfunction in HIV/AIDS. Cell Host Microbe 4, 63-76 (2008).
20. Stacey, A.R.etal. Induction of a striking systemic cytokinecascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast tomore modest and delayed responses in acute hepatitisB and C virus infections. J Virol 83, 3719-3733 (2009).
21. Johnston, M.I. & Fauci, A.S. An HIV vaccine-evolving concepts. N Engl J Med 356, 2073-2081 (2007).
22. Wong, S.B.J. & Siliciano, R.F. Biology of early infection and impact on vaccine design. In AIDS Vaccine Development: Challenges and Opportunities (Koff WC, Kahn P, Gust ID, (eds)) 17-22 (Caister Academic Press: Hethersett, Norwich, UK (2007).
23. Tomaras, G.D. & Haynes, B.F. Strategies for eliciting HIV-1 inhibitory antibodies. Curr Opin HIV AIDS 5, 421-427 (2010).
24. McElrath, M.J. & Haynes, B.F. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 33, 542-554 (2010).
25. Fiebig, E.W. et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. Aids 17, 1871-1879 (2003).
26. Gasper-Smith, N. et al. Induction of plasma (TRAIL), TNFR-2, Fas ligand and plasma microparticles after HIV-1 transmission: implications for HIV-1 vaccine design. J Virol 82, 7700-10 (2008).
27. Cohen, M.S., Shaw, G.M., McMichael, A.J. & Haynes, B.F. Acute HIV-1 infection. N Engl J Med 364, 1943-1954 (2011).
28. Mestecky, J. et al. (eds) Mucosal Immunology, 3rd edn (Elsevier Academic Press: Burlington, MA, USA (2005).
29. Mestecky, J., Moldoveanu, Z. & Russell, M.W. Immunologic uniqueness of the genital tract: challenge for vaccine development.AmJ Reprod Immunol 53, 208-214 (2005).
30. Mestecky, J. et al. Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals. AIDS Res Hum Retrovir 20, 972-988 (2004).
31. Yates, N.L. et al. Multiple HIV-1 specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection. AIDS 25 (17), 2089-97 (2011).
32. Cleghorn, F.R. et al. A distinctive clade B HIV type 1 is heterosexually transmitted in TRINIDAD and Tobago. Proc Natl Acad Sci USA 97, 10532-10537 (2000).
33. Shen, X. et al. In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J Virol 83, 3617-3625 (2009).
34. Liao, H.X. et al. Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med 208, 2237-2249 (2011).
35. Haimovici, F., Mayer, K.H. & Anderson, D.J. Quantitation of HIV-1-specific IgG, IgA, and IgM antibodies in human genital tract secretions. J Acquir Immune Defic Syndr Hum Retrovirol 15, 185-191 (1997).
36. Wolff, H. et al. A comparison of HIV-1 antibody classes, titers, and specificities in paired semen and blood samples from HIV-1 seropositive men. J Acquir Immune Defic Syndr 5, 65-69 (1992).
37. Xu, W. et al. HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits. Nat Immunol 10, 1008-1017 (2009).
38. Konkel, J.E. & Chen, W. Balancingacts:the roleofTGF-betainthe mucosal immune system. Trends Mol Med 17, 668-676 (2011).
39. Morell, A., Skvaril, F., Noseda, G. & Barandun, S. Metabolic properties of human IgA subclasses. Clin Exp Immunol 13, 521-528 (1973).
40. Morell, A., Terry, W.D. & Waldmann, T.A. Metabolic properties of IgG subclasses in man. J Clin Invest 49, 673-680 (1970).
41. Ghetie, V. & Ward, E.S. Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu Rev Immunol 18, 739-766 (2000).
42. Bonsignori, M. et al. HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. J Immunol 183, 2708-2717 (2009).
43. Fouda, G.G. et al. HIV-specific functional antibody responses in breast milk mirror thosein plasma and are primarily mediated by IgG antibodies. JVirol 85, 9555-9567 (2011).
44. Litinskiy, M.B. et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 3, 822-829 (2002).
45. Balazs, M., Martin, F., Zhou, T. & Kearney, J. Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Immunity 17, 341-352 (2002).
46. Scholz, J.L. et al. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc Natl Acad Sci USA 105, 15517-15522 (2008).
47. Fagarasan, S., Kawamoto, S., Kanagawa, O. & Suzuki, K. Adaptive immune regulation in the gut: Tcell-dependent and Tcell-independent IgA synthesis. Annu Rev Immunol 28, 243-273 (2010).
48. Veazey, R.S. et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 280, 427-431 (1998).
49. Mattapallil, J.J. et al. Massive infection and loss of memory CD4+ Tcells in multiple tissues during acute SIV infection. Nature 434, 1093-1097 (2005).
50. Nawa, M. et al. Immunoglobulin A antibody responses in dengue patients: a useful marker for serodiagnosis of dengue virus infection. Clin Diagn Lab Immunol 12, 1235-1237 (2005).
51. Kaul, R.etal. Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection. AIDS 15, 431-432 (2001).
52. Devito, C. etal. Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS 14, 1917-1920 2000).
53. Devito, C. etal. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol 165, 5170-5176 2000).
54. Lo Caputo, S. et al. Mucosal and systemic HIV-1-specific immunity in HIV-1-exposed but uninfected heterosexual men. AIDS 17, 531-539 (2003).
55. Griffiss, J.M. & Goroff, D.K. IgA blocks IgM and IgG-initiated immune lysis by separate molecular mechanisms. J Immunol 130, 2882-2885 (1983).
56. Komiyama, K., Crago, S.S., Itoh, K., Moro, I. & Mestecky, J. Inhibition of natural killer cell activity by IgA. Cell Immunol 101, 143-155 (1986).
57. Haynes, B.F. etal. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366, 1275-1286 (2012).
58. Barouch, D.H. etal. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482, 89-93 (2012).
59. Alfsen, A., Iniguez, P., Bouguyon, E. & Bomsel, M. Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J Immunol 166, 6257-6265 (2001).
60. Clerici, M. etal. Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41. AIDS 16, 1731-1741 2002).
61. Tudor, D.etal. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol 2, 412-426 2009).
62. Liu, P. et al. Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection. J Virol 85, 11196-11207(2011).
63. Belshe, R.B. et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 181, 1133-1137 (2000).
64. Buisman, A.M. et al. Preexisting poliovirus-specific IgA in the circulation correlates with protection against virus excretion in the elderly. J Infect Dis 197, 698-706 (2008).
65. Franco, M.A., Angel, J. & Greenberg, H.B. Immunity and correlates of protection for rotavirus vaccines. Vaccine 24, 2718-2731 (2006).
66. Blattner, W.A. et al. Rapid clearance of virus after acute HIV-1 infection: correlates of risk of AIDS. J Inf Dis 189, 1793-1801 (2004).
67. Yates, N.L etal. Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection. AIDS 25, 2089-2097 (2011).
68. Gao, F. et al. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol 79, 1154-1163 (2005).
69. Morris, L et al. Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PloS one 6, e235322011).